MedTrace Logo

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

NCT02620163 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 381

Last updated 2024-11-12

No results posted yet for this study

Summary

To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment

Conditions

Interventions

DRUG

telmisartan/amlodipine 40/5mg

DRUG

YH22162 40/5/12.5 mg

DRUG

telmisartan/amlodipine 80/5mg

DRUG

YH22162 80/5/25 mg

DRUG

telmisartan/amlodipine 40/5mg placebo

DRUG

YH22162 40/5/12.5 mg placebo

DRUG

telmisartan/amlodipine 80/5mg placebo

DRUG

YH22162 80/5/25 mg placebo

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Hyunhee Na, MD · Yuhan Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02620163 on ClinicalTrials.gov